瑞珍斯生物
RGNX
6.93
-0.24
-3.28%
瑞珍斯生物
US · RGNX
#3748 按市值排名
上市于 2015
6.93
-0.24
-3.28%
实时 - 追踪5344个代码 - 心跳于9秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例下降了13.5个百分点。
机构持股
- 机构持股比例
- 66.07% -13.45pp
- 机构数量
- 206 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund37.71%
Hedge Fund18.35%
Individual/Insider6.69%
Public Company5.93%
Insurance Company1.46%
Private Company1.43%
VC/PE Fund1.12%
Other27.24%
主要股东 截至 2026-06-30
BlackRock
9.69% · 6.40M 股
Redmile Group, LLC
6.62% · 4.37M 股
Allan Fox
4.82% · 3.18M 股
State Street Global Advisors
4.50% · 2.97M 股
Vanguard Capital Management, LLC
3.70% · 2.44M 股
J.P. Morgan Asset Management, Inc.
3.24% · 2.14M 股
Morgan Stanley
2.90% · 1.92M 股
Vanguard Portfolio Management, LLC
2.05% · 1.36M 股
AQR Capital Management
2.05% · 1.35M 股
Marshall Wace LLP
1.95% · 1.28M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 33次买入 · 17次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Allan Fox | Chairperson | 4.82% |
| Kenneth Mills | Chief Executive Officer | 0.67% |
| Vittal Vasista | Chief Financial Officer | 0.29% |
| Gregory Ciongoli | Independent Director | 0.16% |
| Patrick Christmas | Chief Legal Officer | 0.15% |
| Craig Malzahn | Executive Vice President, Product Development & CTO | 0.12% |
| Olivier Danos | Chief Scientific Officer | 0.09% |
| Curran Simpson | Chief Operating Officer | 0.08% |
| Stephen Pakola | Chief Medical Officer | 0.08% |
| Jennifer Zachary | Independent Director | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-31 | Mitchell Chan | Chief Financial Officer | Sale to Issuer | -4,902 | $9.32 |
| 2026-08-31 | Craig Malzahn | Executive Vice President, Product Development & CTO | Sale to Issuer | -234 | $9.32 |
| 2026-08-26 | Gregory Ciongoli | Independent Director | Open Market Acquisition | +102,603 | $9.14–9.36 |
| 2026-08-24 | Gregory Ciongoli | Independent Director | Other Acquisition | +15,432 | -- |
| 2026-08-24 | Gregory Ciongoli | Independent Director | Other Derivative Acquisition | +69,609 | $8.91 |
| 2026-07-31 | Stephen Pakola | Chief Medical Officer | Sale to Issuer | -7,468 | $9.69 |
| 2026-07-31 | Patrick Christmas | Chief Legal Officer | Sale to Issuer | -4,699 | $9.69 |
| 2026-07-01 | Stephen Pakola | Chief Medical Officer | Derivative Exercise and Sale | -2,161 | $7.86–13.64 |
| 2026-06-30 | Curran Simpson | Chief Operating Officer | Sale to Issuer | -6,818 | $13.09 |
| 2026-06-30 | Stephen Pakola | Chief Medical Officer | Derivative Exercise and Sale | -36,725 | $7.86–12.86 |
| 2026-06-29 | Curran Simpson | Chief Operating Officer | Other Acquisition | +2,404 | $7.00–10.18 |
| 2026-06-28 | Stephen Pakola | Chief Medical Officer | Automatic Disposition | -19,608 | $11.04 |
| 2026-05-28 | David Stump | Independent Director | Other Acquisition | +9,807 | -- |
| 2026-05-28 | David Stump | Independent Director | Other Derivative Acquisition | +46,600 | $7.01 |
| 2026-05-28 | George Migausky | Independent Director | Other Acquisition | +9,807 | -- |
| 2026-05-28 | George Migausky | Independent Director | Other Derivative Acquisition | +46,600 | $7.01 |
| 2026-05-28 | Argeris Karabelas | Lead Independent Director | Other Acquisition | +9,807 | -- |
| 2026-05-28 | Argeris Karabelas | Lead Independent Director | Other Derivative Acquisition | +46,600 | $7.01 |
| 2026-05-28 | Allan Fox | Chairperson | Other Acquisition | +9,807 | -- |
| 2026-05-28 | Allan Fox | Chairperson | Other Derivative Acquisition | +46,600 | $7.01 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
瑞珍斯生物 讨论区 0 条评论